Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy
Authors:
- Leonardo CalzaLCLeonardo Calza
- Roberto ManfrediRMRoberto Manfredi
- Barbara FarnetiBFBarbara Farneti
- Francesco ChiodoFCFrancesco Chiodo
- 1 July 2003
- journal article
- clinical trial
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 22 (1) , 54-59
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Factors Related to Lipodystrophy and Metabolic Alterations in Patients with Human Immunodeficiency Virus Infection Receiving Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2002
- Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and LipodystrophyClinical Infectious Diseases, 2001
- Preliminary Guidelines for the Evaluation and Management of Dyslipidemia in Adults Infected with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus GroupClinical Infectious Diseases, 2000
- Coronary Artery Disease and Human Immunodeficiency Virus InfectionClinical Infectious Diseases, 2000
- Serum Triglycerides, HIV Infection, and Highly Active Antiretroviral Therapy, Aquitaine Cohort, France, 1996 to 1998JAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Alterations in Serum Levels of Lipids and Lipoproteins with Indinavir Therapy for Human Immunodeficiency Virus‐Infected PatientsClinical Infectious Diseases, 1999
- Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalitiesThe Lancet, 1998
- Rational Assessment of the Interaction Profile of Cerivastatin Supports its Low Propensity for Drug InteractionsDrugs, 1998
- Micronised FenofibrateDrugs, 1997
- Mechanism of action of gemfibrozil on lipoprotein metabolism.Journal of Clinical Investigation, 1985